Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
Abstract Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A prospective cohort study in which patients are divided into three groups. Group 1: moderate and severe COVID-19 pa...
| المؤلفون الرئيسيون: | , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Nature Portfolio
2023-04-01
|
| سلاسل: | Scientific Reports |
| الوصول للمادة أونلاين: | https://doi.org/10.1038/s41598-023-33484-6 |